Despite Flat Q2, Sanofi Foresees Growth In H2, Fuelled by IO And Rare Blood Units
CEO also says there's still room for more M&A, and that Sanofi is a virtual paragon of US pricing restraint that rivals can learn from.
CEO also says there's still room for more M&A, and that Sanofi is a virtual paragon of US pricing restraint that rivals can learn from.